Research
Hormonal
Semaglutide improves insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue by activating the PI3K/AKT and AMPK/SIRT1 pathways, leading to GLUT4 translocation, independent of direct insulin action in some contexts.
Semaglutide helps your body use insulin better by activating specific cellular pathways (AMPK/SIRT1) that move glucose into muscles and fat cells. This reduces insulin resistance, a key factor in type 2 diabetes and obesity.
ModerateSupportsMEDIUM confidence
semaglutide not only potentiates insulin secretion and alleviates insulin resistance by inducing glucose transporter type 4 (GLUT4) in insulin-sensitive target tissues, mainly skeletal muscle and adipose tissue... Semaglutide may mediate glucose transport through AMPK/SIRT1 because GLP-1RA can activate SIRT1 through cAMP-dependent PKA, and GLUT4 is a downstream of SIRT1
Why this rating
The paper cites preclinical and some clinical evidence for insulin resistance improvement, but notes mechanistic gaps in humans.
Source
Spotlight on the Mechanism of Action of Semaglutide
Ilias Papakonstantinou et al. · Current Issues in Molecular Biology · 2024
DOI 10.3390/cimb46120872
narrative_reviewCited 42×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide reduces cardiovascular risk (MACE) and non-ASCVD deaths (including from infections) in overweight/obese patients with established cardiovascular disease, independent of diabetes status.Strong
- Semaglutide (2.4 mg once weekly) promotes adipose tissue browning and mitochondrial biogenesis via the AMPK/SIRT1/PGC1α/UCP1 axis, enhancing energy expenditure and thermogenesis, although this mechanism is primarily established in preclinical rodent models rather than confirmed in humans.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →